Factorial Partners LLC Acquires 21,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Factorial Partners LLC grew its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 332,000 shares of the company’s stock after acquiring an additional 21,000 shares during the period. Teva Pharmaceutical Industries accounts for 4.2% of Factorial Partners LLC’s portfolio, making the stock its biggest position. Factorial Partners LLC’s holdings in Teva Pharmaceutical Industries were worth $7,317,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in TEVA. Creative Planning raised its holdings in Teva Pharmaceutical Industries by 4.5% in the third quarter. Creative Planning now owns 42,815 shares of the company’s stock valued at $772,000 after acquiring an additional 1,863 shares in the last quarter. Private Advisor Group LLC increased its position in shares of Teva Pharmaceutical Industries by 12.9% in the 3rd quarter. Private Advisor Group LLC now owns 26,104 shares of the company’s stock worth $470,000 after purchasing an additional 2,990 shares during the last quarter. Diversify Advisory Services LLC raised its stake in shares of Teva Pharmaceutical Industries by 95.3% in the 3rd quarter. Diversify Advisory Services LLC now owns 19,859 shares of the company’s stock valued at $365,000 after purchasing an additional 9,693 shares in the last quarter. Diversify Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the third quarter worth about $640,000. Finally, Gladstone Institutional Advisory LLC lifted its position in shares of Teva Pharmaceutical Industries by 847.5% during the third quarter. Gladstone Institutional Advisory LLC now owns 143,939 shares of the company’s stock worth $2,594,000 after purchasing an additional 128,748 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 0.8 %

Shares of Teva Pharmaceutical Industries stock opened at $16.45 on Friday. The stock has a market capitalization of $18.64 billion, a price-to-earnings ratio of -11.34, a PEG ratio of 1.44 and a beta of 0.71. Teva Pharmaceutical Industries Limited has a twelve month low of $12.51 and a twelve month high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The business’s 50 day simple moving average is $19.65 and its 200-day simple moving average is $18.46.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.55% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on TEVA shares. Barclays lowered their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Finally, Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.57.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.